Clobetasol
| Evidence Level: L3 | Predicted Indications: 1 |
Table of Contents
- Clobetasol
- Pharmacist Assessment Report
- Clobetasol: super-potent topical corticosteroid → primary cutaneous T-cell lymphoma
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Clobetasol: super-potent topical corticosteroid → primary cutaneous T-cell lymphoma
One-Sentence Summary
Clobetasol is a super-potent topical glucocorticoid. The TxGNN model predicts it may be useful for primary cutaneous T-cell lymphoma, in particular early-stage mycosis fungoides. This direction is currently supported by 0 registered clinical trials and 15 publications, mostly case reports and small observational studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | primary cutaneous T-cell lymphoma |
| TxGNN Prediction Score | 0.9951 |
| Evidence Level | L3 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Clobetasol is a super-potent topical glucocorticoid. Glucocorticoid receptor activation is thought to induce apoptosis of malignant T cells and to suppress the local inflammatory infiltrate in early-stage (patch/plaque) mycosis fungoides.
Topical corticosteroids are already used as skin-directed therapy for early-stage disease. A review of experience at the University of California, San Francisco, reported that topical clobetasol is first-line treatment for early-stage mycosis fungoides there. This is consistent with the TxGNN prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14686970 | 2003 | Cohort | Dermatologic Therapy | About 200 patients with patch-stage mycosis fungoides treated with mainly high-potency topical corticosteroids; response rate over 90% with minor side effects; clobetasol is first-line at UCSF |
| 32603400 | 2020 | Cohort | Cutis | Observational study of clobetasol propionate 0.05% cream and cutaneous adverse effects in early-stage mycosis fungoides |
| 39741016 | 2025 | Cohort | Anais Brasileiros de Dermatologia | Compares clobetasol propionate with bexarotene in early-stage mycosis fungoides |
| 8987063 | 1996 | Case series | Pediatric Dermatology | Weekly pulse superpotent topical corticosteroid therapy in three children with lymphomatoid papulosis |
| 25027222 | 2014 | Case report | Nederlands Tijdschrift voor Geneeskunde | Child with hypopigmented mycosis fungoides successfully treated with clobetasol 0.05% ointment 4 days a week |
| 36846176 | 2023 | Case report | Clinical Case Reports | Mycosis fungoides with psoriasiform plaques, initially misdiagnosed as psoriasis and treated with topical steroids |
| 28031140 | 2016 | Case report | Skinmed | Cutaneous presentation of angioimmunoblastic T-cell lymphoma, initially treated as psoriasis including topical clobetasol |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10080M | Clobex | Shampoo containing clobetasol propionate 500 micrograms per mL, 125 mL | Not recorded in the local data |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 records, all with an unclassified severity level. Examples include other corticosteroids (triamcinolone, prednisone, prednisolone, hydrocortisone), proton pump inhibitors (omeprazole, pantoprazole, lansoprazole), calcitriol, vitamin A, doxycycline, metronidazole and morphine. Severity has not been graded, so these should be reviewed individually.
- The literature reviewed also raises the concern of long-term cutaneous adverse effects with prolonged topical corticosteroid use in chronic disease such as mycosis fungoides; one observational study (PMID 32603400) specifically examined this.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Several cohort studies and case reports support topical clobetasol in early-stage mycosis fungoides, and the prediction is consistent with current clinical practice. However, there are no registered clinical trials and no randomised evidence. The only Australian product identified is a shampoo, so route and formulation compatibility with skin-directed lymphoma therapy is unconfirmed.
To proceed, the following is needed:
- Confirmation of suitable topical formulations (cream or ointment) available in Australia, as the listed product is a shampoo
- Prospective or randomised data for clobetasol in early-stage mycosis fungoides
- Mechanism of action data
- Warnings and contraindications from the TGA Product Information
- A monitoring plan for local and systemic corticosteroid adverse effects with long-term use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.